Shanghai device price controls to become a pan-China model?
This article was originally published in Clinica
Just over one month ago, on April 1 2003, the Shanghai government established a new pricing method and price ceiling for specific medical technologies, including many implantable devices, writes Ed Rozynski.
You may also be interested in...
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.